Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Qiagen NV (N:QGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: Hulsterweg 82
VENLO 5912 PL
Tel: 49-2103-2911457
Website: https://www.qiagen.com
IR: See website
Key People
Lawrence A. Rosen
Independent Chairman of the Supervisory Board
Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Business Overview
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Financial Overview
For the fiscal year ended 31 December 2023, Qiagen NV revenues decreased 8% to $1.97B. Net income decreased 19% to $341.3M. Revenues reflect Consumables and Related Revenues segment decrease of 9% to $1.73B, Instrumentation segment decrease of 5% to $239.1M, Asia, Pacific & Rest of the World segment decrease of 22% to $320.7M. Net income also reflects Foreign Exchange Gain/Loss decrease from $2.7M (income) to $5.8M (expense).